Retatrutide vs CagriSema (Cagrilintide + Semaglutide): Triple Agonist vs Amylin + GLP-1 Combo

Retatrutide and CagriSema represent two fundamentally different approaches to next-generation obesity treatment. Retatrutide is a single molecule that activates three receptors (GLP-1, GIP, and glucagon). CagriSema is a combination of two separate drugs — cagrilintide (an amylin analog) and semaglutide (a GLP-1 agonist) — delivered together in one injection.

Both are made by different companies (Eli Lilly vs Novo Nordisk), target different biological pathways, and have reported Phase 3 results. CagriSema is further along in the regulatory process, with an NDA filed in December 2025. Retatrutide is still completing Phase 3 trials.

Side-by-Side Comparison

Cagrilintide vs Retatrutide: How the Mechanisms Differ

Retatrutide: Three Receptors, One Molecule

Retatrutide activates GLP-1, GIP, and glucagon receptors simultaneously with a single peptide molecule. The glucagon component is what sets it apart — it increases energy expenditure through thermogenesis and promotes fat oxidation, particularly in the liver. This means retatrutide attacks obesity from both sides of the energy equation: reduced intake (GLP-1 + GIP) and increased expenditure (glucagon).

For details on each receptor, see How Does Retatrutide Work?.

CagriSema: Two Drugs Working Together

CagriSema combines two separate mechanisms:

Cagrilintide (2.4 mg) is a long-acting analog of amylin, a hormone co-secreted with insulin from pancreatic beta cells after meals. Amylin promotes satiety by acting on both homeostatic and hedonic (reward) brain regions via the area postrema. It slows gastric emptying and suppresses post-meal glucagon secretion. Cagrilintide is engineered with prolonged action through reversible albumin binding, enabling once-weekly dosing.

Semaglutide (2.4 mg) is the same GLP-1 agonist in Wegovy/Ozempic — the most well-established obesity drug on the market.

The combination targets appetite through two complementary brain pathways (amylin + GLP-1), producing additive weight loss beyond what either component achieves alone. In REDEFINE 1, CagriSema (-22.7%) significantly outperformed both cagrilintide alone (-11.8%) and semaglutide alone (-16.1%).

The Key Difference

Retatrutide includes glucagon receptor agonism, which increases energy expenditure — your body burns more calories at rest. CagriSema does not increase energy expenditure. Instead, it stacks two different appetite suppression pathways (amylin + GLP-1).

This likely explains why retatrutide produces greater maximum weight loss (-28.7% vs -22.7%) — the glucagon component adds thermogenic effects on top of appetite reduction.

Cagrilintide vs Retatrutide vs Tirzepatide: Receptor Targets

Retatrutide and CagriSema each cover pathways the other does not. Retatrutide has GIP and glucagon but no amylin agonism. CagriSema has amylin agonism but no GIP or glucagon. Tirzepatide overlaps with retatrutide on GLP-1 and GIP but lacks both glucagon and amylin.

Weight Loss Comparison

Phase 3 Results

Weight Loss Thresholds (CagriSema, REDEFINE 1)

CagriSema in Type 2 Diabetes (REDEFINE 2)

In adults with type 2 diabetes, CagriSema produced -15.7% weight loss at 68 weeks vs -3.1% for placebo. Weight loss is consistently lower in diabetic populations across all GLP-1 class drugs. Retatrutide's dedicated T2D Phase 3 program (TRANSCEND) has not yet reported results.

Important Caveat

These results come from different trials with different patient populations. TRIUMPH-4 enrolled patients with obesity and knee osteoarthritis (445 participants). REDEFINE 1 enrolled a broader obesity population (3,417 participants). The only definitive comparison would be a randomized head-to-head trial, which does not exist.

Side Effects and Tolerability

CagriSema's lower discontinuation rate (~6%) compared to retatrutide (12-18%) is notable. Retatrutide's unique dysesthesia signal — tingling, burning, or prickling sensations on the skin — occurred in up to 20.9% of participants on the 12 mg dose and is being monitored in ongoing trials. This is likely related to the glucagon receptor and is not seen with CagriSema or other GLP-1 drugs.

Regulatory Timeline

CagriSema is approximately one year ahead of retatrutide in the regulatory timeline. If approved in 2026, it would be the first amylin + GLP-1 combination therapy on the market.

Can You Combine Cagrilintide With Retatrutide?

People searching for "cagrilintide with retatrutide" or "cagrilintide and retatrutide together" are asking about stacking these two peptides. Here is what the evidence says.

The Scientific Rationale

There is a plausible theoretical basis for combining them. Cagrilintide activates amylin receptors — a pathway that retatrutide does not touch. Together, they would cover four distinct receptor systems (GLP-1, GIP, glucagon, and amylin), potentially producing greater appetite suppression and weight loss than either drug alone.

This rationale is supported by CagriSema's own clinical data. In REDEFINE 1, adding cagrilintide to semaglutide produced 22.7% weight loss compared to 16.1% for semaglutide alone — demonstrating that amylin agonism meaningfully enhances GLP-1-based weight loss. In principle, the same additive effect could apply to retatrutide.

Eli Lilly appears to recognize this logic. The company is studying eloralintide, its own amylin receptor agonist, in combination with tirzepatide in a Phase 2 trial — suggesting that amylin + incretin combinations are an active area of pharmaceutical development.

What the Data Actually Shows

No clinical trial has studied cagrilintide and retatrutide together. Zero published safety or efficacy data exists for this combination. The two drugs are made by competing companies (Novo Nordisk and Eli Lilly), making a formal combination study unlikely.

Safety Concerns

Without clinical data, safety risks can only be inferred:

• Additive GI side effects — both drugs slow gastric emptying through different mechanisms. Combining them could increase nausea, vomiting, and gastroparesis risk beyond what either drug causes alone.
• Excessive appetite suppression — amylin agonism is a potent appetite suppressant. Combined with retatrutide's triple mechanism, caloric intake could drop to levels that promote muscle loss and nutritional deficiencies.
• No long-term safety data — neither drug has multi-year safety data on its own, let alone in combination.

The Bottom Line

The scientific rationale for combining amylin agonism with incretin-based therapy is real and supported by CagriSema's clinical results. However, no data exists for the specific cagrilintide + retatrutide combination. Anyone considering this combination should discuss it with their physician.

Frequently Asked Questions

Sources

• Novo Nordisk. (2025). Novo Nordisk files for FDA approval of CagriSema. Press release.
• Aronne, L.J., et al. (2025). Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. DOI: 10.1056/NEJMoa2502081
• Novo Nordisk. (2025). REDEFINE 2 results. GlobeNewsWire.
• Eli Lilly. (2025). TRIUMPH-4 results. Press release.
• Sonne, N., et al. (2025). Amylin — mode of action, from bench side to clinical potential. Diabetologia. PMC12085449
• Chung, J.S., et al. (2025). Triple agonism based therapies for obesity. Springer. PMC12304053

Medical Disclaimer

The content on glp3.wiki is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Both retatrutide and CagriSema are investigational drugs. CagriSema has been submitted for FDA review but is not yet approved.

Do not use this information to make decisions about your health without consulting a qualified healthcare provider. If you are considering weight loss medication, talk to your doctor about currently approved options.

This site is not affiliated with Eli Lilly, Novo Nordisk, or any pharmaceutical manufacturer.